Alexion On Its AstraZeneca Integration And Growth Plan
An Interview With Senior VP-US Commercial Operations Scott Weintraub
Two years after being acquired by AstraZeneca, the company remains relatively autonomous in rare disease, but with “bridges” to its big pharma parent.
